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Abstract: The management of chronic lymphocytic leukemia (CLL) has dramatically improved 
in the past decade with the addition of anti-CD20 monoclonal antibodies to the treatment 
armamentarium. Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved 
in the US and Europe for the treatment of CLL refractory to alemtuzumab and fludarabine. 
Preclinical data showed improved complement-dependent cytotoxicity and antibody-dependent 
cellular cytotoxicity compared with rituximab. Clinical studies have shown single-agent activity 
for ofatumumab in CLL and in other low-grade non-Hodgkin’s lymphomas. Combination studies 
are being conducted to enhance the therapeutic efficacy of ofatumumab. This paper reviews 
some of the key clinical studies that led to approval of ofatumumab, and future directions.
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Introduction
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most 
common leukemia in the Western hemisphere, with an age-adjusted incidence rate 
of 4.2 per 100,000 men and women per year.1 It is a monoclonal B cell malignancy 
that affects mainly older individuals, with a median age at diagnosis of 72 years. The 
spectrum of this disease varies from a simple lymphocytosis to splenomegaly and/or 
cytopenias. Some patients have an indolent course, while others have a more accelerated 
course. In either case, the disease relapses frequently, and there is considerable 
  morbidity from the disease and the treatments themselves.2
Several predictive factors have been identified in CLL. In addition to clinical 
staging, traditional prognostic factors for identifying high risk of disease progression 
have included elevated serum levels of beta-2 microglobulin, soluble CD23,   diffuse 
bone marrow infiltration, short lymphocyte doubling time, and high levels of 
  zeta-associated protein on the surface of malignant cells.3,4 More recently, the presence 
of certain cytogenetic abnormalities identified by fluorescence in situ hybridization 
analysis and mutational status of immunoglobulin heavy chain have become a more 
meaningful predictor of disease progression and duration of response to therapy.5
The median survival is highly variable, with some patients following an indolent 
course with a survival of over 20 years, whereas others exhibit an aggressive 
behavior with survival less than three years. The management of patients with 
CLL/SLL is   currently undergoing profound changes. Historically, the approach to 
management of CLL focused on reducing tumor bulk and controlling symptoms, while 
maintaining a good quality of life. Treatment options for decades included alkylating Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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agents, purine analogs, or a combination of the two. More 
effective combination regimens, such as fludarabine, 
cyclophosphamide, and rituximab, have recently been shown 
to prolong progression-free survival and overall survival, 
thereby changing the treatment paradigm to one with a 
goal of complete elimination of the disease in patients who 
are younger or older but physically fit. Because there is no 
proven survival benefit of early treatment of asymptomatic 
patients, most patients are followed by watchful waiting 
until symptoms develop. Although most patients with 
CLL respond to first-line therapy, all patients eventually 
relapse, after which the therapeutic options are limited 
and the prognosis is particularly poor after development of 
fludarabine-refractory disease.
Preclinical data
Addition of the CD20 monoclonal antibody, rituximab, to 
chemotherapy for CLL has improved outcomes, particularly 
in early lines of therapy. Typically CLL cells have low CD20 
expression, which helps explain why the efficacy of rituximab 
monotherapy in CLL is limited, potentially in part because 
of reduced cell lysis via complement-dependent cytotoxicity, 
which is dependent on CD20 expression.
Ofatumumab is an IgG1κ, fully humanized CD20 mono-
clonal antibody that targets an epitope distinct from the 
epitope recognized by rituximab. The antibody is generated 
via transgenic mouse and hybridoma technology and 
produced in a recombinant murine cell line (NS0) using 
standard   mammalian cell cultivation and   purification 
  technologies.6 The mechanism of action of ofatumumab 
was studied indepth, and compared with that of the 
  marketed chimeric anti-CD20 monoclonal antibody, 
  rituximab.   Ofatumumab binds specifically to epitopes which 
  encompass the amino acid residues 163 and 166 in the   second 
extracellular loop of the CD20 molecule.   Ofatumumab 
induces crosslinking of CD20 molecules and relocation 
of these CD20 molecules to the so-called lipid rafts.7 The 
  translocation of CD20 into lipid rafts is considered important 
for induction of cell signaling and more effective complement 
activation.8 Differences in antibody function between 
various anti-CD20   antibodies might be explained by their 
distinct ability to induce   relocation of the CD20 molecules 
within the lipid rafts. The binding of ofatumumab induces cell 
death, primarily through   complement-dependent cytotoxicity 
and antibody-dependent cellular cytotoxicity and not by 
  apoptosis. Ofatumumab has similar antibody-dependent 
  cellular cytotoxicity when compared with rituximab, but 
delivers stronger complement-dependent cytotoxicity 
in in vitro models, even in malignant B cells with low 
CD20 expression levels.6,9 Laboratory studies have shown 
  ofatumumab to be effective at inducing lysis of several B cell 
lines, as well as being able to kill fresh CLL B cells resistant 
to rituximab.6,9,10
Further studies have demonstrated that although ofatu-
mumab and rituximab bind the same antigen, ofatumumab 
dissociates from its target at a slower rate compared with 
rituximab,6 and binds a novel, membrane-proximal epitope. 
In experiments using radiolabeled antibodies, more than 
70% of ofatumumab, but only 30% of rituximab, remained 
bound to deoxyhypusine hydroxylase cells after three hours. 
Epitope mapping has indicated that ofatumumab binds an 
epitope located closer to the N-terminus of CD20 compared 
with the location targeted by rituximab, and includes an 
extracellular loop of the antigen. It is hypothesized that the 
complement-dependent potent cytotoxicity of ofatumumab 
may be due to both the slow off-rate and the precise location 
of binding on CD20 compared with rituximab.10
To evaluate the in vivo efficacy of ofatumumab, its 
effect was tested in a mouse xenograft model.11 Severe 
combined immunodeficiency mice were first injected with 
Daudi B cells transfected with luciferase, and then treated 
with either 0.5 mg/kg of ofatumumab or anti- keyhole limpet 
hemocyanin monoclonal antibody as a control. Tumor growth 
was assessed by bioluminescence. A single dose, resulting 
in an initial plasma antibody concentration of 5 µg/mL, 
expected to result in full target saturation, effectively inhibited 
human B cell tumor development. Tumor growth resumed 
when plasma concentrations dropped below levels that are 
expected to result in half-maximal saturation. Compared with 
the control group, the ofatumumab cohort showed delayed 
tumor induction (3–4 weeks) and lower tumor growth rate. 
In cynomolgus monkeys, initial depletion of circulating 
and tissue-residing B cells required a relatively high dose 
level. A 1.25 mg/kg intravenous (IV) dose administered 
daily for four days effectively depleted B cells. Initial 
plasma concentrations were approximately 50 µg/mL, and 
repopulation of B cell compartments only became detectable 
when ofatumumab levels dropped below 10 µg/mL. The cell 
count did not return to a normal level until 96 days later, but 
the animals developed primate antihuman antibodies. The 
results of these animal studies suggested that high initial 
dosing would be necessary to saturate CD20, but maintenance 
of a plasma concentration at 5–10 µg/mL maintains target 
saturation on circulating cells and is probably sufficient for 
sustained biological activity.11 These observations may provide 
a rationale for establishing dosing schedules for maintenance Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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immunotherapy following initial depletion of CD20-positive 
tumor cells. These data suggest that ofatumumab may 
deplete B cells for a longer period of time than rituximab, 
which may lead to a longer duration of treatment response 
and could potentially result in a smaller dose being needed. 
Ofatumumab is a human monoclonal antibody with very 
low anticipated immunogenicity. Therefore, subjects are not 
expected to produce human antihuman antibodies to the same 
degree as the human antichimeric antibodies seen in some 
subjects following treatment with rituximab. Based on these 
in vivo studies, clinical studies of ofatumumab were initiated 
in different diseases, including B cell malignancies, such 
as CLL. The following section reviews the current clinical 
data on ofatumumab in CLL, as well as future therapeutic 
directions.
Clinical studies of ofatumumab  
in CLL
The Table 1 summarizes completed and ongoing clinical 
studies of ofatumumab in CLL/SLL. A Phase I/II dose-
escalating study evaluating ofatumumab in patients with 
relapsed and refractory CLL was initiated at 12 sites in the 
US and Europe. This study evaluated 33 patients in three 
different dosing cohorts.12 The majority of patients (27/33) 
received a total of four doses administered once weekly. 
The response rate for the cohort receiving an initial dose of 
500 mg followed by three 2000 mg doses was 50%, with 
partial remission observed in 13/26 patients. The drug was 
well tolerated, with the majority of adverse events being 
related to infusion reactions and Grade 1 and 2 infections.
A second larger study was done evaluating patients 
with CLL refractory to alemtuzumab and fludarabine. The 
interim analysis of this pivotal international study evaluated 
a total of 138 patients (59 were refractory to fludarabine and 
alemtuzumab [FA-ref] and 79 were refractory to fludarabine 
but did not receive treatment with alemtuzumab due to 
bulky disease [BF-ref]).13 Ofatumumab was administered as 
eight weekly infusions followed by four monthly infusions. 
The first infusion was given as a 300 mg dose and the 
subsequent infusions were given at a dose of 2000 mg. The 
objective response rate was found to be 58% and 47% in 
the FA-ref and BF-ref groups, respectively. All of these 
were partial responses, with the exception of one complete 
response. Complete resolution of constitutional symptoms 
and improved performance status occurred in 57% and 48% 
of FA-ref and BF-ref patients, respectively. The response 
was also significant in those who received prior rituximab 
therapy (objective response rate 54% in the FA-ref patients 
and 44% in the BF-ref patients) as well as those who 
received prior treatment with the combination of fludarabine, 
cyclophosphamide, and rituximab (objective response rate of 
50% and 44% in the FA-ref and BF-ref groups, respectively). 
Furthermore, ofatumumab was also active in those having 
a 17p deletion, with a response rate of 41% in the FA-ref 
group, although the response was lower at 14% in the BF-ref 
group with 17p deletion. The median time to response 
was 1.8 months, and the median duration of response was 
7.1 months in the FA-ref group and 5.6 months in the 
BF-ref group. Median progression-free survival and overall 
survival times were 5.7 and 13.7 months in the FA-ref group, 
respectively, and 5.9 and 15.4 months in the BF-ref group, 
respectively. The most common adverse events occurring 
during treatment were infections (67%) and infusion-related 
reactions (seen in 64% of patients in the FA-ref group and 
61% of patients in the BF-ref group), nearly all of which were 
Grade 1 or 2. These reactions predominantly occurred during 
the first and second infusions, subsided during the course 
of treatment, and included cough (18%), diarrhea (16%), 
anemia (16%), fatigue (15%), fever (15%), neutropenia 
(15%), dyspnea (13%), nausea (11%), and rash (10%). No 
human antihuman antibodies were detected in any of the 
evaluable patients. This study led to accelerated approval of 
ofatumumab in patients with CLL refractory to fludarabine 
and alemtuzumab by the US Food and Drug Administration 
in October 2009.
The final results for the primary endpoint of this study 
for 206 enrolled patients were reported at the 2010 American 
Society of Hematology annual meeting. The objective 
response rate by independent endpoint review committee 
evaluation was 51% for the FA-ref group and 44% for 
the BF-ref group. Two patients in the BF-ref group achieved 
a complete response. The median duration of response was 
5.7 months in the FA-ref group and six months in the BF-ref 
group. Progression-free survival and overall survival were 
5.5 months and 14.2 months for the FA-ref group, and 
5.5 months and 17.4 months for the BF-ref group.14
Another single-arm Phase II study currently recruiting 
patients is investigating the effects of ofatumumab 
retreatment and maintenance in CLL patients who received 
the monoclonal antibody in a previous study (study number 
Hx-CD20-406). Patients will receive eight weekly infusions 
(300 mg, then seven × 2000 mg doses), followed by 2000 mg 
doses once a month for two years. The study is expected to 
enroll 25 patients, and primary outcome measures should 
be reported after January 2012 (clinicaltrials.gov study 
#NCT00802737).Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Following on from the single-agent results, studies 
evaluating ofatumumab combined with other chemotherapeutic 
agents have recently been undertaken. One of these studies 
was a two-dose parallel group, international, randomized, 
multicenter Phase II study looking at ofatumumab combined 
with fludarabine and cyclophosphamide (O-FC) in patients 
with previously untreated CLL.15 A total of 61 patients were 
randomized to receive ofatumumab 500 mg (Group A) or 
1000 mg (Group B) on day 1, combined with fludarabine 
(25 mg/m2 IV daily on days 1–3) and cyclophosphamide 
(250 mg/m2 IV daily on days 1–3) every four weeks for 
a total of six courses. In both groups, the first dose of 
ofatumumab was 300 mg. The complete response rate was 
32% for Group A and 50% for Group B, and the objective 
response rate was 77% and 73%, respectively. After a median 
follow-up duration of eight months, the median progression-
free survival has not been reached. This study demonstrates 
the activity of ofatumumab combined with fludarabine and 
cyclophosphamide in previously untreated patients with 
CLL, and although the objective response rate of O-FC was 
lower when compared with historical controls, the rate of 
complete response was higher when compared with patients 
having similar prognostic risk. Overall, the patients in the 
O-FC trial were reportedly of high risk, which was primarily 
determined by an elevated β2-microglobulin. Furthermore, 
a study evaluating 224 patients treated with fludarabine, 
cyclophosphamide, and rituximab in the frontline setting 
showed a complete response rate of 72% and an objective 
response rate of 95%. However, this study had a lower 
number of patients with Rai Stage III–IV disease of 36% 
compared with 45% in the O-FC trial.16
Another study, recently reported at the 2010 American 
Society of Clinical Oncology meeting, showed a historic 
objective response rate of 92% and complete response rate 
of 66% for fludarabine, cyclophosphamide, and rituximab in 
previously untreated CLL patients.17 On the other hand, updated 
results of the German CLL Study Group for fludarabine and 
cyclophosphamide versus fludarabine, cyclophosphamide, 
and rituximab in the frontline setting revealed an objective 
response rate of 95.1% for the fludarabine, cyclophosphamide, 
and rituximab arm, but only a complete response rate of 
44.1%.18 Another study evaluated bendamustine combined 
with rituximab in the frontline setting and showed an objective 
response rate of 90% with only a complete response rate of 
32%.19 Due to patient differences, it is hard to make comparisons 
using historical data. O-FC seems to be a promising and active 
regimen in the upfront setting, but Phase III data would likely 
be necessary to determine further its definite role.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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The initial results of a Phase II study evaluating the 
efficacy and tolerability of the combination of lenalidomide 
and ofatumumab in patients with relapsed CLL was recently 
presented at the 2010 American Society of Hematology 
meeting.20 In this trial, ofatumumab was administered IV 
weekly for four weeks (300 mg week 1, 1000 mg week 2, 
and all subsequent doses), then monthly for months 2–6 
and once every two months for months 7–24. Lenalidomide 
was given orally at a dose of 10 mg daily, starting on day 9 
and continued daily. The treatment duration was 24 months. 
Results for the first 16 of 40 planned patients who have been 
on study for at least three months were presented. Four 
patients (25%) were refractory to fludarabine and all patients 
had received prior rituximab. Ten of the 16 evaluable patients 
achieved a response (two complete responses [13%], eight 
partial responses [50%]) for an objective response rate of 
63%. Four patients with stable disease were continuing on 
treatment. The most common Grade 3–4 treatment-related 
adverse events observed were neutropenia (eight patients, 
50%) and anemia (two patients, 13%). Lenalidomide-
associated tumor flare reaction was limited to Grade 1 in two 
patients (13%). The authors concluded that the combination 
was therapeutically active in patients with relapsed CLL and 
was well tolerated.
The combination of high-dose methylprednisolone and 
ofatumumab was recently reported in patients with CLL not 
considered to be good candidates for chemotherapy due to 
comorbidities, poor performance status, profound cytopenia, 
or refractory status to fludarabine and/or alemtuzumab.21 
Eight patients with progressive, symptomatic CLL were 
treated with high-dose methylprednisolone 1 g/m2 IV daily 
every 28 days for three consecutive cycles, and a single dose 
of ofatumumab 300 mg, followed by 11 doses of 2000 mg 
over a six-month period. The median patient age was 
69 years, and the median number of prior treatments was 4.5, 
including four patients who had previously received high-dose 
methylprednisolone and rituximab and two patients who had 
undergone matched unrelated donor stem cell transplantation. 
All patients had been previously treated with rituximab, 
75% had failed or were intolerant to fludarabine and/or 
alemtuzumab, and 75% had high-risk prognostic markers, 
including unfavorable cytogenetics, unmutated IgVH region 
genes, or high expression levels of zeta-associated protein. 
Most of the patients had bulky disease and splenomegaly. 
All patients completed the planned therapy with no major 
side effects or toxicities. There was no evidence of marrow 
suppression, and even patients with pancytopenia improved 
their peripheral blood counts with this salvage regimen. 
The objective response rate was 50% (four partial remissions), 
25% of patients had stable disease, and the remainder showed 
progressive disease. These data suggest that the combination 
of high-dose methylprednisolone and ofatumumab is a safe 
and effective salvage regimen for high-risk CLL patients who 
otherwise would not be candidates for additional treatment. 
Further clinical studies of this combination are warranted.
Conclusion
Ofatumumab has significant antileukemic activity, and offers 
another effective agent with which to improve the outcome 
of patients with CLL/SLL. Further studies will clarify the 
optimal dose and time to use this drug. CLL refractory to 
fludarabine is a high-risk disease that has very few treatment 
options. In this regard, ofatumumab seems to be an effective 
agent. However, in the previously untreated CLL setting, we 
do not believe any of the current studies can justify using 
this therapy over one of the other more established and   cost-
effective regimens, such as fludarabine, cyclophosphamide, 
and rituximab. Ongoing clinical trials will determine the role 
of ofatumumab in CLL in both the upfront and the relapsed 
setting. Furthermore, randomized Phase III clinical trials will 
be required to determine if ofatumumab is a clinical advance 
over rituximab.
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